cisplatin + decitabine

Cisplatin + decitabine is a combination therapy that pairs cisplatin, a platinum-based chemotherapeutic agent, with decitabine, a DNA methyltransferase inhibitor. This combination has shown synergistic effects in treating various cancers, particularly in overcoming cisplatin resistance. Decitabine works by inhibiting DNA methyltransferases, leading to DNA hypomethylation and reactivation of silenced genes, while cisplatin forms DNA crosslinks that interfere with cell division. The combination has demonstrated enhanced efficacy in preclinical and clinical studies for multiple cancer types including relapsed/refractory diffuse large B-cell lymphoma, gastric cancer, ovarian cancer, and head and neck squamous cell carcinoma.